146 related articles for article (PubMed ID: 30358609)
1. Unexpected PAX8 Immunoreactivity in Metastatic High-grade Breast Cancer.
Kilgore MR; Bosch DE; Adamson KH; Swanson PE; Dintzis SM; Rendi MH
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):637-643. PubMed ID: 30358609
[TBL] [Abstract][Full Text] [Related]
2. Polyclonal PAX8 expression in carcinomas of the biliary tract - Frequent non-specific staining represents a potential diagnostic pitfall.
Zong Y; Xiong Y; Dresser K; Yang M; Bledsoe JR
Ann Diagn Pathol; 2021 Aug; 53():151762. PubMed ID: 34102541
[TBL] [Abstract][Full Text] [Related]
3. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
4. Utility of monoclonal PAX8 antibody for distinguishing intrathyroid thymic carcinoma from follicular cell-derived thyroid carcinoma.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Tanaka A; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2018 Dec; 65(12):1171-1175. PubMed ID: 30210064
[TBL] [Abstract][Full Text] [Related]
5. Comparison of PAX8 Expression in Breast Carcinoma Using MRQ50 and BC12 Monoclonal Antibodies.
Singh K; Hanley LC; Sung CJ; Quddus MR
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):558-561. PubMed ID: 31335489
[TBL] [Abstract][Full Text] [Related]
6. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
Woodard AH; Yu J; Dabbs DJ; Beriwal S; Florea AV; Elishaev E; Davison JM; Krasinskas AM; Bhargava R
Am J Clin Pathol; 2011 Sep; 136(3):428-35. PubMed ID: 21846919
[TBL] [Abstract][Full Text] [Related]
7. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison.
Ozcan A; Liles N; Coffey D; Shen SS; Truong LD
Am J Surg Pathol; 2011 Dec; 35(12):1837-47. PubMed ID: 21989345
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Paired Box 8 (PAX8)-expressing Metastatic Breast Carcinoma.
Kim SW; Kim HS; Na K
Anticancer Res; 2020 Oct; 40(10):5925-5932. PubMed ID: 32988924
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
10. PAX8 Expression in Breast Cancer.
Lu S; Yakirevich E; Hart J; Wang L; Wang Y
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):293-298. PubMed ID: 33208672
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusions.
Wiseman W; Michael CW; Roh MH
Diagn Cytopathol; 2011 Sep; 39(9):651-6. PubMed ID: 20949455
[TBL] [Abstract][Full Text] [Related]
12. PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases.
Fujiwara M; Taube J; Sharma M; McCalmont TH; Kim J
J Cutan Pathol; 2010 Sep; 37(9):938-43. PubMed ID: 20492080
[TBL] [Abstract][Full Text] [Related]
13. PAX2 and PAX8: useful markers for metastatic effusions.
Waters L; Crumley S; Truong L; Mody D; Coffey D
Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997
[TBL] [Abstract][Full Text] [Related]
14. Do You Know the Details of Your PAX8 Antibody? Monoclonal PAX8 (MRQ-50) Is Not Expressed in a Series of 45 Medullary Thyroid Carcinomas.
Gucer H; Caliskan S; Kefeli M; Mete O
Endocr Pathol; 2020 Mar; 31(1):33-38. PubMed ID: 31912298
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
[TBL] [Abstract][Full Text] [Related]
16. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis.
Weissferdt A; Moran CA
Am J Surg Pathol; 2011 Sep; 35(9):1305-10. PubMed ID: 21836478
[TBL] [Abstract][Full Text] [Related]
17. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
Nonaka D; Chiriboga L; Soslow RA
Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243
[TBL] [Abstract][Full Text] [Related]
18. Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics.
Chen X; Arend R; Hamele-Bena D; Tergas AI; Hawver M; Tong GX; Wright TC; Wright JD
Int J Gynecol Pathol; 2017 Sep; 36(5):412-419. PubMed ID: 28700424
[TBL] [Abstract][Full Text] [Related]
19. PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin.
Tacha D; Qi W; Zhou D; Bremer R; Cheng L
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):59-63. PubMed ID: 22595948
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic and prognostic analysis of PAX8 and TTF-1 expressions in neuroendocrine carcinomas of thymic origin: A comparative study with their pulmonary counterparts.
Bi Y; Deng Y; Li S; Zhou X; Chen Y; Ma D; Mao X; Guan Y; Chen J; Meng Y
J Surg Oncol; 2016 Nov; 114(6):697-702. PubMed ID: 27761900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
